Provista President and CEO David E. Reese Ph.D. Presents Company Overview and Videssa® Breast at Sachs Associates European Life Science CEO Forum & Exhibition

NEW YORK, March 16, 2016 /PRNewswire/ -- Provista President and CEO David E. Reese, Ph.D. presented at the 9^th Annual European Life Science CEO Forum and Exhibition in Zurich. Dr. Reese provided an overview of Provista and Videssa® Breast, the first blood test of its kind to provide early and accurate detection of breast cancer, scheduled to launch later this year.

Logo - http://photos.prnewswire.com/prnh/20160316/345091LOGO

Dr. Reese's corporate update featured data showing that Videssa Breast accurately identified patients with breast cancer when combined with imaging. In clinical trials, the combination of this blood test with diagnostic imaging also showed a reduction in the probability of a woman undergoing a biopsy that will ultimately be designated a false positive for cancer. Videssa Breast will give physicians and patients additional objective and accurate information to make treatment decisions.

"In the field of diagnostics, innovative companies will need to occupy the intersection of true scientific advances and unmet clinical needs to create meaningful impact," said Dr. Reese. "That's exactly what we've done at Provista, by applying the science of proteomics to address the tremendous need women and clinicians have in the field of breast cancer." 

Dr. Reese was also asked to sit on the Sachs Diagnostics and Imaging Panel, meant to explore the state of current science and advancing technologies in diagnostics.

"I am honored to have been asked to present at the Sachs Associates CEO Forum and enjoyed discussing Provista's latest advances in diagnostic technology with the panel," said Dr. Reese. "Using ProteoMark® technology as its basis, Videssa Breast will provide patients and their physicians accurate diagnoses quickly to help improve outcomes and relieve the burden of uncertainty."   

About Videssa® Breast

Videssa Breast is the first blood test of its kind, using Provista's patented ProteoMark technology that examines multiple Serum Protein Biomarkers (SPBs) and Tumor-Associated Autoantibodies (TAAbs), combined with patient clinical data to detect, the presence or absence of breast cancer for early and accurate detection.

Videssa Breast is a proteomic test that analyzes specific types of protein biomarkers in the blood and also measures the presence of TAAbs, which are developed by the body to mount an attack against the specific cancer cells.  Using both SPBs and TAAbs, a proprietary algorithm generates a high or low 'signature' report associated with the presence or absence of early breast cancer. 

The combination of imaging (anatomical evidence) with a proteomic approach (biochemical evidence) offers a powerful detection method and provides important additional information for providers. Videssa Breast transforms the breast cancer detection paradigm and applies proteomic testing to bring clarity to imaging results.

About Provista

Provista Diagnostics is a privately held molecular diagnostics company focused on developing and commercializing a new generation of proprietary blood-based diagnostic, prognostic and monitoring tests designed to address the unmet needs in women's cancer, such as breast and gynecologic cancers. Provista Diagnostics' state-of-the-art, high-complexity clinical laboratory is accredited by the College of American Pathologists (CAP) and certified by the Centers for Medicare and Medicaid Services (CMS) to be compliant with the Clinical Laboratory Improvement Amendments (CLIA).

Additional information about Provista Diagnostics is available at ProvistDx.com

Information about Provista Diagnostics' clinical trials is available at ClinicalTrials.gov

Safe Harbor Statement

Statements contained in this communication not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Provista's actual results may differ materially due to a number of factors, many of which are beyond Provista's ability to predict or control, including among others, viability and effectiveness of our sales approach and overall marketing strategies, the outcome of development or regulatory review of our products, commercial success or acceptance by the medical community, competitive responses, our ability to raise additional capital, and the ability to successfully file a registration statement with the SEC. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. Provista operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Provista undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.

Media Contact:

Susan LaMacchia

212-202-3174

Email

SOURCE Provista Diagnostics

Related Links

http://www.provistadx.com